Industry news that matters to you.  Learn more

Archives for November 2011

Functional Brain Pathways Disrupted in Children with ADHD

Using functional magnetic resonance imaging (fMRI), researchers have identified abnormalities in the brains of children with attention deficit/hyperactivity disorder (ADHD) that may serve as a biomarker for the disorder, according to a study presented today at the annual meeting of the Radiological Society of North America (RSNA).

GVK Biosciences Announces Multi-year Drug Discovery Collaboration with the Moulder Center for Drug Discovery Research, Temple University

GVK Biosciences, Asia’s leading drug discovery research & development organization, announced today that it has entered into a drug discovery alliance with the Moulder Center for Drug Discovery Research at Temple University.

As part of the multi-year integrated drug discovery collaboration, GVK BIO will be responsible for the target validation, lead identification and lead optimization of small molecules in selected therapeutic areas, including cardiovascular, metabolic, and central nervous system disorders.

AMP Announces Completion of Strategic Plan For Era of Personalized Medicine

The Association for Molecular Pathology (AMP) recently announced the AMP Council’s unanimous approval of a strategic plan intended to guide the organization over the next four years.

The plan’s completion follows a comprehensive Council review of AMP’s mission and strategic direction. The process was also informed by multiple surveys of membership and elected leadership, as well as numerous field interviews.

Massachusetts General Cancer Center and Vall d’Hebron Institute of Oncology Biomarker Alliance

The President of the BBVA Foundation, Francisco González, Jose Baselga, Chief of Hematology/Oncology at Massachusetts General Hospital Cancer Center (MGHCC), and Andrés de Kelety, Managing Director at the Vall d’Hebrón Institute of Oncology (VHIO) in Barcelona, last week signed an agreement creating the BBVA Foundation Tumor Biomarkers Research Program. Also attending the event was the Foundation’s Director, Mr. Rafael Pardo.

AQUA Technology Expands to Additional Digital Pathology Platform with Launch of Vectra 2 from Caliper Life Sciences

Caliper Life Sciences, a Perkin-Elmer Company, launched their new Vectra 2 with AQUA technology, an integrated solution for quantification of protein biomarkers in tissue, at the Molecular Targets & Cancer Therapeutics meeting this week. Caliper and HistoRx collaborated on this new immunofluorescent imaging and analysis solution that will deliver objective, quantitative, and reproducible results: an improvement on traditional immunohistochemistry. The new product enables users to leverage the combined imaging and analysis power of Caliper’s Vectra 2, an automated multiplexed and multispectral tissue imaging platform, and AQUA technology, HistoRx’s proprietary image analysis system, to provide an integrated solution to advance the identification and validation of new drug targets and improve assessment of drug response.